MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Zimmer Biomet Holdings Revenue 2011-2026 | ZBH
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Zimmer Biomet Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.68 B | 7.39 B | 6.94 B | 6.83 B | 6.13 B | 7.98 B | 7.93 B | 7.82 B | 7.68 B | 6 B | - | 4.62 B | 4.47 B | 4.45 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.98 B | 4.45 B | 6.61 B |
Quarterly Revenue Zimmer Biomet Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 B | 2.08 B | 1.91 B | 1.82 B | 1.94 B | 1.89 B | 1.75 B | 1.87 B | 1.83 B | - | 1.67 B | 1.78 B | 1.66 B | - | 1.69 B | 2.03 B | 1.6 B | 2.09 B | 1.93 B | 1.23 B | 1.78 B | 2.13 B | 1.89 B | 1.99 B | 1.98 B | 2.07 B | 1.84 B | 2.01 B | 2.02 B | 2.07 B | 1.81 B | 1.95 B | 1.97 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.12 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.13 B | 1.12 B | 1.86 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Helius Medical Technologies
HSDT
|
644 K | $ 2.22 | 2.55 % | $ 1.35 M |  USA |
 |
OrthoPediatrics Corp.
KIDS
|
236 M | $ 17.26 | 1.29 % | $ 405 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | USA |
 |
LivaNova PLC
LIVN
|
1.39 B | $ 66.29 | 15.11 % | $ 3.62 B |  Britain |
 |
Myomo
MYO
|
40.9 M | $ 0.84 | -4.25 % | $ 35.2 M | USA |
 |
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | USA |
 |
Orthofix Medical
OFIX
|
822 M | $ 12.33 | -0.88 % | $ 488 M |  Curacao |
 |
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | USA |
 |
Alphatec Holdings
ATEC
|
764 M | $ 7.12 | -30.45 % | $ 1.07 B | USA |
 |
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.56 | 3.04 % | $ 133 M |  France |
 |
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | USA |
 |
Insulet Corporation
PODD
|
2.71 B | $ 150.99 | -9.88 % | $ 10.6 B | USA |
 |
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | USA |
 |
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | USA |
 |
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | USA |
 |
Sintx Technologies
SINT
|
1.02 M | $ 2.47 | 1.86 % | $ 6.85 M | USA |
 |
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | USA |
 |
Stryker Corporation
SYK
|
7.17 B | $ 291.1 | -1.42 % | $ 111 B | USA |
 |
ClearPoint Neuro
CLPT
|
37 M | $ 11.61 | 4.59 % | $ 329 M | USA |
 |
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | USA |
 |
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | USA |
 |
TransMedics Group
TMDX
|
605 M | $ 71.46 | -24.72 % | $ 2.43 B | USA |
 |
Tandem Diabetes Care
TNDM
|
290 M | $ 18.18 | -6.39 % | $ 1.24 B | USA |
 |
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.58 | -3.93 % | $ 36.1 M | USA |
 |
Delcath Systems
DCTH
|
85.2 M | $ 11.38 | -1.34 % | $ 408 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M |  Canada |
 |
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.03 | -1.9 % | $ 17.4 M | USA |
 |
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | USA |
 |
Varex Imaging Corporation
VREX
|
845 M | $ 11.95 | 3.6 % | $ 495 M | USA |
 |
Electromed
ELMD
|
64 M | $ 26.01 | 0.76 % | $ 220 M | USA |
 |
Vivos Therapeutics
VVOS
|
17.4 M | $ 0.71 | 0.65 % | $ 7.29 M | USA |
 |
Butterfly Network
BFLY
|
82.1 M | $ 4.66 | -3.32 % | $ 986 M | USA |
 |
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | USA |
 |
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | USA |
 |
Globus Medical
GMED
|
2.94 B | $ 89.64 | -0.43 % | $ 12.1 B | USA |
 |
CONMED Corporation
CNMD
|
1.37 B | $ 36.89 | 0.68 % | $ 1.14 B | USA |
 |
Inspire Medical Systems
INSP
|
912 M | $ 46.24 | -4.17 % | $ 1.36 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.85 B | $ 86.32 | 0.55 % | $ 3 B | USA |
 |
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 82.62 | -0.35 % | $ 48.3 B | USA |